The Genomic Landscape of Breast Cancer in Young and Older Women
Clinical Breast Cancer · 2024
DOI: 10.1016/j.clbc.2024.07.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2024. Verfasst von Arielle L Heeke und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Atrium Health, Charlotte, NC; Sandra Levine Young Women…. Hauptthemen laut MEDLINE: Breast Neoplasms, Mutation, Biomarkers, Tumor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Young women with breast cancer (YWBC; ≤40 years) often have a poorer prognosis than older women with breast cancer (OWBC; ≥65 years). We explored molecular features of tumors from YWBC and OWBC to identify a biologic connection for these patterns. MATERIALS AND METHODS: We retrospectively analyzed the molecular profiles of 1879 breast tumors. Testing included immunohistochemistry (IHC), in situ hybridization (ISH), and next-generation sequencing. Statistical analyses included Pearson's chi2 test for comparisons, with significance defined as FDR (false discovery rate)-P < .05. RESULTS: TP53 and BRCA1 somatic mutations were more common in YWBC tumors than in OWBC tumors (53%, 42%; P = .0001, FDR-P = .0025 and 7%, 2%; P = .0001, FDR-P = .0025; respectively). Conversely, OWBC tumors had higher androgen receptor expression (55%, 45%; P = .0002, FDR-P = .0025) higher PD-L1 expression detected by IHC (8%, 5%; P = .0476, FDR-P = .2754), and more frequent PIK3CA mutations (33%, 17%; P = < .0001, FDR-P = < .0001). Among HR+/HER2- samples, YWBC had more gene amplifications in FGF3 (27%, 10%; P = .0353, FDR-P = .2462), FGF4 (27%, 9%; P = .0218, FDR-P = .1668), FGF19 (30%, 12%; P = .034, FDR-P = .2462) and CCND1 (37%, 18%; P = .0344, FDR-P = .2462) than OWBC. CONCLUSIONS: Our data suggest distinct molecular aberrations exist between YWBC and OWBC. Exploiting these molecular changes could refine our treatment strategies in YWBC and OWBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Atrium Health, Charlotte, NC; Sandra Levine Young Women's Breast Cancer Program, Levine Cancer Institute, Atrium Health, Char…
- Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC.
- Caris Life Sciences, Phoenix, AZ.
- Division of Surgical Oncology, Department of Surgery, Carolinas Medical Center, Levine Cancer Institute, Atrium Health, Charlotte, NC; Sandra Levine Young Women's Breast Cancer Program, Levine Cancer Institute, Atrium H…
Zitieren
APA
Heeke, A. L., Sha, W., Feldman, R., Fisher, J., Hadzikadic-Gusic, L., Symanowski, J. T., White, R. L., & Tan, A. R. (2024). The Genomic Landscape of Breast Cancer in Young and Older Women. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.07.008
Vancouver
Heeke AL, Sha W, Feldman R, Fisher J, Hadzikadic-Gusic L, Symanowski JT, et al. The Genomic Landscape of Breast Cancer in Young and Older Women. Clinical Breast Cancer. 2024. doi:10.1016/j.clbc.2024.07.008
BibTeX
@article{Heeke2024,
author = {Heeke, Arielle L and Sha, Wei and Feldman, Rebecca and Fisher, Julie and Hadzikadic-Gusic, Lejla and Symanowski, James T and White, Richard L and Tan, Antoinette R},
title = {The Genomic Landscape of Breast Cancer in Young and Older Women},
journal = {Clinical Breast Cancer},
year = {2024},
doi = {10.1016/j.clbc.2024.07.008}
}
EUVIMED